Hazard
134 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.
Of the 134 injectable recalls we have scored against our rubric, 6 (4%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1 (1%) are Severe.
Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all injectable recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.
A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes for lack of assurance of sterility, following an FDA observation of deficiencies in visual inspection at the contract manufacturing site.
Fresenius Kabi is recalling one batch of 0.9% Sodium Chloride Injection, USP in 1,000 mL single dose freeflex bags distributed by BD, citing lack of assurance of sterility.
Fagron is recalling norepinephrine bitartrate 16 mg in 250 mL sodium chloride bags for lack of assurance of sterility and because a blue break-off part could detach from the administration port.
GE Healthcare is recalling Omnipaque (iohexol) Injection, 300 mg/mL, over the presence of particulate matter. The action covers 866,570 vials distributed nationwide.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 50 mL presentation distributed by BD, citing lack of assurance of sterility.
Teva is recalling nine lots of Octreotide Acetate for Injectable Suspension 20 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva is recalling twelve lots of Octreotide Acetate for Injectable Suspension after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva is recalling two lots of Octreotide Acetate for Injectable Suspension 10 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
New Life Pharma is recalling one lot of Semaglutide Injection 2 mg sterile multi-dose vials for lack of assurance of sterility.
New Life Pharma is recalling one lot of Tirzepatide Injection 10 mg sterile multi-dose vials for lack of assurance of sterility.
New Life Pharma is recalling one lot of Tirzepatide Injection 15 mg x 4 sterile multi-dose vials for lack of assurance of sterility.
New Life Pharma is recalling two lots of Semaglutide Injection 2 mg x 10 sterile multi-dose vials for lack of assurance of sterility.
Cipla USA is recalling 15,221 prefilled syringes of Lanreotide Injection, 120 mg/0.5 mL, over the presence of particulate matter.
Novo Nordisk is recalling Wegovy (semaglutide) Injection, 1 mg/0.5 mL prefilled pens, over the presence of particulate matter after hair was found in a prefilled syringe.
Novo Nordisk is recalling Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL prefilled pens, over the presence of particulate matter after hair was found in a prefilled syringe.
Fresenius Kabi is recalling 2,199,850 vials of Famotidine Injection USP after out of limit results were obtained for endotoxin testing. The FDA classified it Class I.
Otsuka ICU Medical is recalling one lot of Potassium Chloride Injection because the overwrap label may state 10 mEq when the product is 20 mEq. The FDA classified it Class I.
Otsuka ICU Medical is recalling 21,696 containers of Potassium Chloride Injection 20 mEq in 50 mL because the overwrap may state 10 mEq. The FDA classified it Class I.
Otsuka ICU Medical is recalling 509,360 100 mL bags of 0.9% Sodium Chloride Injection from one lot for lack of assurance of sterility due to potential flexible container leaks.
Samsung Bioepis is recalling 5,518 cartons, 11,036 prefilled syringes, of HADLIMA (adalimumab-bwwd) injection 40mg/0.8 mL from one lot for lack of assurance of sterility.
ProRx is recalling 2,805 vials of Semaglutide Injection 5 mg/2 mL from one lot for lack of assurance of sterility.
ProRx is recalling 8,400 vials of Semaglutide Injection 10 mg/4 mL for lack of assurance of sterility.
ProRx is recalling 2,649 vials of Semaglutide Injection 2.5 mg/1 mL from one lot for lack of assurance of sterility.
ProRx is recalling 11,119 vials of Semaglutide Injection 8 mg/3.2 mL across four lots for lack of assurance of sterility.
QuVa Pharma is recalling 75,885 syringes of its R.E.C.K. periarticular injection over the presence of particulate matter.